BSE Live
Apr 20, 11:56Prev. Close
24.26
Open Price
25.00
Bid Price (Qty.)
24.51 (25)
Offer Price (Qty.)
25.39 (15)
NSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
| Cash Flow of ANG Lifesciences India (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | -12.94 | -8.87 | 2.07 | 53.06 | 7.03 | |
| Net CashFlow From Operating Activities | -2.29 | -13.13 | 26.01 | 27.39 | 9.14 | |
| Net Cash Used In Investing Activities | -1.63 | 20.02 | -9.35 | -42.50 | -7.70 | |
| Net Cash Used From Financing Activities | 3.92 | -7.00 | -16.75 | 15.29 | -1.19 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -0.01 | -0.12 | -0.08 | 0.17 | 0.26 | |
| Cash And Cash Equivalents Begin of Year | 0.09 | 0.20 | 0.29 | 0.11 | 3.60 | |
| Cash And Cash Equivalents End Of Year | 0.08 | 0.09 | 0.20 | 0.29 | 3.86 |
10.03.2026
ANG Lifescience Consolidated December 2025 Net Sales at Rs 18.73 crore, down 24.25% Y-o-Y
04.12.2025
ANG Lifescience Consolidated September 2025 Net Sales at Rs 26.05 crore, down 20.77% Y-o-Y
27.11.2025
ANG Lifescience Standalone September 2025 Net Sales at Rs 25.97 crore, down 19.24% Y-o-Y
12.06.2025
ANG Lifescience Standalone March 2025 Net Sales at Rs 17.67 crore, down 48.16% Y-o-Y
10.03.2026
ANG Lifescience Consolidated December 2025 Net Sales at Rs 18.73 crore, down 24.25% Y-o-Y
04.12.2025
ANG Lifescience Consolidated September 2025 Net Sales at Rs 26.05 crore, down 20.77% Y-o-Y
27.11.2025
ANG Lifescience Standalone September 2025 Net Sales at Rs 25.97 crore, down 19.24% Y-o-Y
12.06.2025
ANG Lifescience Standalone March 2025 Net Sales at Rs 17.67 crore, down 48.16% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth